Argos Therapeutics, Inc. (ARGS) Posts Q2 Loss of 61c/Share

Argos Therapeutics, Inc. (NASDAQ: ARGS) reported Q2 EPS of ($0.61), $0.01 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $1.27 million.

For earnings history and earnings-related data on Argos Therapeutics, Inc. (ARGS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49